Methods of using substituted morpholine derivatives

A method of treating a bipolar disorder comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds of formula I:

• wherein:
• q is 0 or 1;
• W is O;
• X is CO;
• Z is O;
• R1 is selected from the group consisting of halogen, cyano, C1-6-alk(en/yn)yl, C3-8-cycloalk(en)yl, C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, halo-C1-6-alk(en/yn)yl, halo-C3-8-cycloalk(en)yl, halo-C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, C1-3-alk(en/yn)yloxy, C5-6-alk(en/yn)yloxy, C4-alkenyloxy, C4-alkynyloxy, C3-8-cycloalk(en)yloxy and C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yloxy;
• R2 is selected from the group consisting of halogen, cyano, C1-6-alk(en/yn)yl, C3-8-cycloalk(en)yl, C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, halo-C1-6-alk(en/yn)yl, halo-C3-8-cycloalk(en)yl, halo-C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, C1-6-alk(en/yn)yloxy, C3-8-cycloalk(en)yloxy, C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yloxy, phenyl and pyridyl;
• wherein the phenyl and the pyridyl are optionally substituted with one or more substituents that are independently halogen, C1-6-alk(en/yn)yl, C3-8-cycloalk(en)yl or C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl;
• R3 is C1-10-alk(en/yn)yl;
• and
• R4, R5, R6 and R7 are each independently selected from the group consisting of hydrogen and an optionally substituted aromatic group of 5-10 carbon atoms, wherein:
• 1, 2, 3 or 4 carbon atoms may be replaced by a heteroatom, each heteroatom independently being N, S, or O;
• the aromatic group is selected from the group consisting of phenyl, naphthyl, pyridine, thiophene, furan, thiazole, quinoline, indole, 2,3-dihydro-benzofuran, pyrimidine, pyrrole, and oxazole;
• and
• the optional substituent is selected from the group consisting of hydroxy, halogen, C1-6-alk(en/yn)yl, C3-8-cycloalk(en)yl, C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, halo-C1-6-alk(en/yn)yl, C1-6-alk(en/yn)yloxy, C3-8-alk(en/yn)yl acyl, nitro, cyano, —CO—NH—C1-6-alk(en/yn)yl, —CO—N(C1-6-alk(en/yn)yl)2, —NH2, —NH—C1-6-alk(en/yn)yl, —N(C1-6-alk(en/yn)yl)2, —S—C1-6-alk(en/yn)yl, —SO2—C1-6-alk(en/yn)yl, —SO2N(C1-6-alk(en/yn)yl)2 and —SO2NH—C1-6-alk(en/yn)yl;
• or
• a pharmaceutically acceptable salt thereof.

A method of treating a bipolar disorder comprising administering to a subject in

• need thereof a therapeutically effective amount of one or more compounds of formula I:
• wherein:
• g is 0 or 1;
• W is O;
• X is CO;
• Z is O;
• R1 is selected from the group consisting of halogen, cyano, C1-6-alk(en/yn)yl, C3-8-cycloalk(en)yl, C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, halo-C1-6-alk(en/yn)yl, halo-C3-8-cycloalk(en)yl, halo-C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, C1-3-alk(en/yn)yloxy, C5-6-alk(en/y n)yloxy, C4-alkenyloxy, C4-alkynyloxy, C3-8-cycloalk(en)yloxy and C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yloxy;
• R2 is selected from the group consisting of halogen, cyano, C1-6-alk(en/yn)yl, C3-8-cycloalk(en)yl, C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, halo-C1-6-alk(en/yn)yl, halo-C3-8-cycloalk(en)yl, halo-C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, C1-3-alk(en/yn)yloxy, C5-6-alk(en/yn)yloxy, C4-alkenyloxy, C4-alkynyloxy, C3-8-cycloalk(en)yloxy, C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yloxy, phenyl and pyridyl;
• wherein the phenyl and the pyridyl are optionally substituted with one or more substituents that are independently halogen, C1-6-alk(en/yn)yl, C3-8-cycloalk(en)yl or C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl,
• R3 is C1-10-alk(en/yn)yl;
• and
• R4, R5, R6 and R7 are each independently selected from the group consisting of hydrogen and an optionally substituted aromatic group of 5-10 carbon atoms, wherein:
• 1, 2, 3 or 4 carbon atoms may be replaced by a heteroatom, each heteroatom independently being N, S, or O;
• the aromatic group is selected from the group consisting of phenyl, naphthyl, pyridine, thiophene, furan, thiazole, quinoline, indole, 2,3-dihydro-benzofuran, pyrimidine, pyrrole, and oxazole;
• and
• the optional substituent is selected from the group consisting of hydroxy, halogen, C1-6-alk(en/yn)yl, C3-8-cycloalk(en)yl, C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, halo-C1-6-alk(en/yn)yl, C1-6-alk(en/y n)yloxy, C3-8-alk(en/yn)yloxy, acyl, nitro, cyano, —CO—NH—C1-6-alk(en/yn)yl, —CO—N(C1-6-alk(en/yn)yl)2, —NH2, —NH—C1-6-alk(en/yn)yl, —N(C1-6-alk(en/yn)yl)2, —S—C1-6-alk(en/yn)yl, —SO2—C1-6-alk(en/yn)yl, —SO2N(C1-6-alk(en/yn)yl)2 and —SO2NH—C1-6-alk(en/yn)yl;
• or
• a pharmaceutically acceptable salt thereof.